Benefits and safety of long-acting calcium antagonists in coronary artery disease: The Action trial

Journal of Hypertension

Volumn 23, Issue 3, 2005, Pages 489-491

  Fagard, Robert H ^a,b  

^a KU LEUVEN DEPARTMENT OF REHABILITATION SCIENCES   (Belgium)

^b UNIVERSITY HOSPITALS LEUVEN   (Belgium)

Author keywords

[No Author keywords available]

Indexed keywords

CALCIUM CHANNEL BLOCKING AGENT; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; LONG ACTING DRUG; NIFEDIPINE; NITRENDIPINE;

ADULT; ANGINA PECTORIS; ANGIOCARDIOGRAPHY; CARDIOVASCULAR DISEASE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CORONARY ARTERY BYPASS GRAFT; CORONARY ARTERY DISEASE; DIASTOLIC BLOOD PRESSURE; DRUG DOSE REGIMEN; DRUG EFFECT; DRUG SAFETY; EDITORIAL; HEART FAILURE; HEART INFARCTION; HEART LEFT VENTRICLE EJECTION FRACTION; HUMAN; HYPERTENSION; MAJOR CLINICAL STUDY; META ANALYSIS; MORTALITY; MULTICENTER STUDY; OUTCOMES RESEARCH; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; REVASCULARIZATION; RISK BENEFIT ANALYSIS; RISK FACTOR; STATISTICAL SIGNIFICANCE; STROKE; SYSTEMATIC REVIEW; SYSTOLIC BLOOD PRESSURE;

EID: 18844416597     PISSN: 02636352     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.hjh.0000160202.35910.d6     Document Type: Editorial

References (14)

1. Lubsen J, Roole-Wilson PA, Pocock SJ, van Dalen FJ, Bauman J, Kirwan BA, Parker AB. Design and current status of ACTION: A Coronary disease Trial Investigating Outcome with Nifedipine GITS. Eur Heart J 1998; 19(suppl I):I20-I32.
2. Ad Hoc Subcommittee of the Liaison Committee of the World Health Organisation and the International Society of Hypertension. Effects of calcium antagonists on the risks of coronary heart disease, cancer and bleeding. J Hypertens 1997; 15:105-115.
3. Poole-Wilson PA, Lubsen J, Kirwan BA, van Dalen FJ, Wagener G, Danchin N, et al. Effect of long-acting nifedipine on mortality and cardiovascular morbidity in patients with stable angina requiring treatment (ACTION trial): randomised controlled trial. Lancet 2004; 364:849-857.
4. Lubsen J, Wagener G, Kirwan BA, de Brouwer S, Poole-Wilson PA, on behalf of the ACTION investigators. Effect of long-acting nifedipine on mortality and cardiovascular morbidity in patients with symptomatic stable angina and hypertension: the ACTION trial. J Hypertens 2005; 23:643-650.
5. Nissen SE, Tuzcu EM, Libby P, Thompson PD, Ghali M, Garza D, et al. Effect of antihypertensive agents on cardiovascular events in patients with coronary disease and normal blood pressure. The CAMELOT study: a randomized controlled trial. JAMA 2004; 292:2217-2226.
6. Pitt B, Byington RP, Furberg CD, Hunninghake DB, Mancini J, Miller ME, et al. Effect of amlodipine on the progression of atherosclerosis and the occurrence of clinical events. Circulation 2000; 102:1503-1510.
7. Dens JA, Desmet WJ, Coussement P, De Scheerder IK, Kostopoulos K, Kerdsinchai P, et al. Long term effects of nisoldipine on the progression of coronary atherosclerosis and the occurrence of clinical events: the NICOLE study. Heart 2003; 89:887-892.
8. Staessen JA, Fagard R, Thijs L, Celis H, Arabidze GG, Birkenhäger WH, et al. Randomised double-blind comparison of placebo and active treatment for older patients with isolated systolic hypertension. Lancet 1997; 350:757-764.
9. Liu L, Wang JG, Gong L, Liu G, Staessen JA. Comparison of active treatment and placebo in older Chinese patients with isolated systolic hypertension. J Hypertens 1998; 16:1823-1829.
10. Blood Pressure Lowering Treatment Trialists' Collaboration. Effects of different blood-pressure-lowering regimens on major cardiovascular events: results of prospectively designed overviews of randomised trials. Lancet 2003; 362:1527-1535.
11. Heart Outcomes Prevention Evaluation Study Investigators. Effects of an angiotensin-converting-enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients. N Engl J Med 2000; 342:145-153.
12. The EURopean trial On reduction of cardiac events with Perindopril in stable coronary Artery disease Investigators. Efficacy of perindopril in reduction of cardiovascular events among patients with stable coronary artery disease: randomised, double-blind, placebo-controlled, multicentre trial (the EUROPA study). Lancet 2003; 362:782-788.
13. Julius S, Kjeldsen SE, Weber M, Brunner HR, Ekman S, Hansson L, et al. Outcomes in hypertensive patients at high cardiovascular risk treated with regimens based on valsartan or amlodipine; the VALUE randomized trial. Lancet 2004; 363:2022-2031.
14. The PEACE Trial Investigors. Angiotensin-converting-enzyme inhibition in stable coronary artery disease. N Engl J Med 2004; 351:2058-2068.